The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer.

Front Oncol · 2019 · PMC6768009 · PMID 31608224

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

We hypothesize that although different ALK fusion variants might contribute to different crizotinib PFS, the impact may not be significant after adjusting for clinical factors.

also in 2,774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.